| Demographics, n (%) . | Overall Cohort (n = 239) . | Proactive TDM (n = 165) . | Reactive TDM (n = 74) . | P-value . |
|---|---|---|---|---|
| Female | 108 (45) | 76 (46) | 32 (43) | .78 |
| Median age at time of induction, years (IQR) | 39 (30-49) | 41 (33-50) | 32 (22-45) | <.01 |
| Median weight at time of escalation, kg (IQR) | 79 (63-92) | 80 (66-93) | 75 (62-88) | .10 |
| Disease duration, years (IQR) | 4.5 (1.2-8.7) | 5.8 (1.2-9.3) | 3.0 (1-7.8) | .11 |
| Montreal classification—age at onset | ||||
| A1 <16 years | 55 (23%) | 32 (19) | 23 (31) | .11 |
| A2—17-40 years | 158 (66%) | 114 (69) | 44 (59) | .08 |
| A3 >40 years | 26 (11%) | 19 (12) | 7 (10) | .31 |
| Montreal classification—disease location | ||||
| L1—ileal | 36 (15) | 17 (10) | 19 (26) | .16 |
| L2—colonic | 70 (29) | 57 (35) | 13 (18) | .08 |
| L3—ileocolonic | 130 (55) | 88 (53) | 42 (57) | .31 |
| L4—isolated upper GI | 3 (1) | 3 (2) | 0 (0) | .07 |
| Montreal classification—disease behavior | ||||
| B1—uncomplicated | 84 (35) | 44 (27) | 40 (54) | <.01 |
| B2—stricturing | 82 (34) | 61 (37) | 21 (28) | .15 |
| B3—penetrating | 73 (31) | 60 (36) | 13 (18) | <.01 |
| Perianal disease | 132 (55) | 92 (56) | 40 (54) | .89 |
| Prior surgery | 115 (48) | 87 (53) | 28 (38) | .04 |
| Current smoker | 48 (20) | 40 (24) | 8 (11) | .02 |
| Tumor Necrosis Factor Naïve | 173 (72) | 111 (67) | 62 (84) | <.01 |
| Infliximab escalation | 126 (53) | 88 (53) | 38 (51) | .78 |
| Adalimumab escalation | 113 (47) | 77 (47) | 36 (49) | .78 |
| Concurrent Immunomodulator use | 152 (64) | 111 (67) | 41 (55) | .08 |
| Anti-TNF drug level availability at time of escalation | 182 (76) | 128 (78) | 54 (73) | .17 |
| Anti-TNF drug level at escalation, median (IQR) | 3.3 (1.7-5.1) | 3.1 (1.7-5.0) | 3.6 (1.8-5.2) | .08 |
| Demographics, n (%) . | Overall Cohort (n = 239) . | Proactive TDM (n = 165) . | Reactive TDM (n = 74) . | P-value . |
|---|---|---|---|---|
| Female | 108 (45) | 76 (46) | 32 (43) | .78 |
| Median age at time of induction, years (IQR) | 39 (30-49) | 41 (33-50) | 32 (22-45) | <.01 |
| Median weight at time of escalation, kg (IQR) | 79 (63-92) | 80 (66-93) | 75 (62-88) | .10 |
| Disease duration, years (IQR) | 4.5 (1.2-8.7) | 5.8 (1.2-9.3) | 3.0 (1-7.8) | .11 |
| Montreal classification—age at onset | ||||
| A1 <16 years | 55 (23%) | 32 (19) | 23 (31) | .11 |
| A2—17-40 years | 158 (66%) | 114 (69) | 44 (59) | .08 |
| A3 >40 years | 26 (11%) | 19 (12) | 7 (10) | .31 |
| Montreal classification—disease location | ||||
| L1—ileal | 36 (15) | 17 (10) | 19 (26) | .16 |
| L2—colonic | 70 (29) | 57 (35) | 13 (18) | .08 |
| L3—ileocolonic | 130 (55) | 88 (53) | 42 (57) | .31 |
| L4—isolated upper GI | 3 (1) | 3 (2) | 0 (0) | .07 |
| Montreal classification—disease behavior | ||||
| B1—uncomplicated | 84 (35) | 44 (27) | 40 (54) | <.01 |
| B2—stricturing | 82 (34) | 61 (37) | 21 (28) | .15 |
| B3—penetrating | 73 (31) | 60 (36) | 13 (18) | <.01 |
| Perianal disease | 132 (55) | 92 (56) | 40 (54) | .89 |
| Prior surgery | 115 (48) | 87 (53) | 28 (38) | .04 |
| Current smoker | 48 (20) | 40 (24) | 8 (11) | .02 |
| Tumor Necrosis Factor Naïve | 173 (72) | 111 (67) | 62 (84) | <.01 |
| Infliximab escalation | 126 (53) | 88 (53) | 38 (51) | .78 |
| Adalimumab escalation | 113 (47) | 77 (47) | 36 (49) | .78 |
| Concurrent Immunomodulator use | 152 (64) | 111 (67) | 41 (55) | .08 |
| Anti-TNF drug level availability at time of escalation | 182 (76) | 128 (78) | 54 (73) | .17 |
| Anti-TNF drug level at escalation, median (IQR) | 3.3 (1.7-5.1) | 3.1 (1.7-5.0) | 3.6 (1.8-5.2) | .08 |
| Demographics, n (%) . | Overall Cohort (n = 239) . | Proactive TDM (n = 165) . | Reactive TDM (n = 74) . | P-value . |
|---|---|---|---|---|
| Female | 108 (45) | 76 (46) | 32 (43) | .78 |
| Median age at time of induction, years (IQR) | 39 (30-49) | 41 (33-50) | 32 (22-45) | <.01 |
| Median weight at time of escalation, kg (IQR) | 79 (63-92) | 80 (66-93) | 75 (62-88) | .10 |
| Disease duration, years (IQR) | 4.5 (1.2-8.7) | 5.8 (1.2-9.3) | 3.0 (1-7.8) | .11 |
| Montreal classification—age at onset | ||||
| A1 <16 years | 55 (23%) | 32 (19) | 23 (31) | .11 |
| A2—17-40 years | 158 (66%) | 114 (69) | 44 (59) | .08 |
| A3 >40 years | 26 (11%) | 19 (12) | 7 (10) | .31 |
| Montreal classification—disease location | ||||
| L1—ileal | 36 (15) | 17 (10) | 19 (26) | .16 |
| L2—colonic | 70 (29) | 57 (35) | 13 (18) | .08 |
| L3—ileocolonic | 130 (55) | 88 (53) | 42 (57) | .31 |
| L4—isolated upper GI | 3 (1) | 3 (2) | 0 (0) | .07 |
| Montreal classification—disease behavior | ||||
| B1—uncomplicated | 84 (35) | 44 (27) | 40 (54) | <.01 |
| B2—stricturing | 82 (34) | 61 (37) | 21 (28) | .15 |
| B3—penetrating | 73 (31) | 60 (36) | 13 (18) | <.01 |
| Perianal disease | 132 (55) | 92 (56) | 40 (54) | .89 |
| Prior surgery | 115 (48) | 87 (53) | 28 (38) | .04 |
| Current smoker | 48 (20) | 40 (24) | 8 (11) | .02 |
| Tumor Necrosis Factor Naïve | 173 (72) | 111 (67) | 62 (84) | <.01 |
| Infliximab escalation | 126 (53) | 88 (53) | 38 (51) | .78 |
| Adalimumab escalation | 113 (47) | 77 (47) | 36 (49) | .78 |
| Concurrent Immunomodulator use | 152 (64) | 111 (67) | 41 (55) | .08 |
| Anti-TNF drug level availability at time of escalation | 182 (76) | 128 (78) | 54 (73) | .17 |
| Anti-TNF drug level at escalation, median (IQR) | 3.3 (1.7-5.1) | 3.1 (1.7-5.0) | 3.6 (1.8-5.2) | .08 |
| Demographics, n (%) . | Overall Cohort (n = 239) . | Proactive TDM (n = 165) . | Reactive TDM (n = 74) . | P-value . |
|---|---|---|---|---|
| Female | 108 (45) | 76 (46) | 32 (43) | .78 |
| Median age at time of induction, years (IQR) | 39 (30-49) | 41 (33-50) | 32 (22-45) | <.01 |
| Median weight at time of escalation, kg (IQR) | 79 (63-92) | 80 (66-93) | 75 (62-88) | .10 |
| Disease duration, years (IQR) | 4.5 (1.2-8.7) | 5.8 (1.2-9.3) | 3.0 (1-7.8) | .11 |
| Montreal classification—age at onset | ||||
| A1 <16 years | 55 (23%) | 32 (19) | 23 (31) | .11 |
| A2—17-40 years | 158 (66%) | 114 (69) | 44 (59) | .08 |
| A3 >40 years | 26 (11%) | 19 (12) | 7 (10) | .31 |
| Montreal classification—disease location | ||||
| L1—ileal | 36 (15) | 17 (10) | 19 (26) | .16 |
| L2—colonic | 70 (29) | 57 (35) | 13 (18) | .08 |
| L3—ileocolonic | 130 (55) | 88 (53) | 42 (57) | .31 |
| L4—isolated upper GI | 3 (1) | 3 (2) | 0 (0) | .07 |
| Montreal classification—disease behavior | ||||
| B1—uncomplicated | 84 (35) | 44 (27) | 40 (54) | <.01 |
| B2—stricturing | 82 (34) | 61 (37) | 21 (28) | .15 |
| B3—penetrating | 73 (31) | 60 (36) | 13 (18) | <.01 |
| Perianal disease | 132 (55) | 92 (56) | 40 (54) | .89 |
| Prior surgery | 115 (48) | 87 (53) | 28 (38) | .04 |
| Current smoker | 48 (20) | 40 (24) | 8 (11) | .02 |
| Tumor Necrosis Factor Naïve | 173 (72) | 111 (67) | 62 (84) | <.01 |
| Infliximab escalation | 126 (53) | 88 (53) | 38 (51) | .78 |
| Adalimumab escalation | 113 (47) | 77 (47) | 36 (49) | .78 |
| Concurrent Immunomodulator use | 152 (64) | 111 (67) | 41 (55) | .08 |
| Anti-TNF drug level availability at time of escalation | 182 (76) | 128 (78) | 54 (73) | .17 |
| Anti-TNF drug level at escalation, median (IQR) | 3.3 (1.7-5.1) | 3.1 (1.7-5.0) | 3.6 (1.8-5.2) | .08 |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
